Anixa Biosciences Inc., a biotechnology company dedicated to cancer treatment and prevention, has announced a forthcoming presentation on its Phase 1 clinical trial for an ovarian cancer CAR-T immunotherapy. Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center and the trial's principal investigator, will present the e-poster at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2025. The event is scheduled to take place from June 19-21, 2025, in Vienna, Austria. The trial involves autologous T-cells genetically engineered with a chimeric receptor aimed at targeting the follicle stimulating hormone receptor (FSHR) in recurrent ovarian cancer. The presentation will provide insights into the preliminary findings of this ongoing study.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。